Over the past 18 months, the Cadonilimab Injection industry trends have been reshaped by a flurry of strategic alliances and capital infusions. Akeso Biopharma’s $200 million Series C+ (closed Q2 2023) accelerated the build-out of a 20,000-L bioreactor suite in Zhongshan, securing regional supply for the bifunctional PD-1/CTLA-4 antibody. The asset then attracted Pfizer’s China-centric licensing deal (Sept 2023) that couples Cadonilimab with Pfizer’s oncology portfolio, giving the multinational 50 % co-promotion rights in non-small-cell lung cancer—an indication poised for 2024 NMPA approval. Regulatory momentum followed: NMPA accepted the first sBLA for peri-operative hepatocellular carcinoma (Dec 2023), a patient segment with no approved checkpoint inhibitor, and simultaneously granted Breakthrough Therapy designation for first-line esophageal squamous cell carcinoma, shortening review timelines from 18 to 8 months. Meanwhile, CSPC NovoTek’s acquisition of a 30 % stake in the underlying CHO-K1 platform (Jan 2024) signals a shift toward contract-development models, allowing mid-tier pharma to access the bispecific without full asset purchase. Collectively, these moves are compressing clinical-to-commercial cycles and pushing average treatment costs down 12 %, catalyzing hospital formulary adoption across tier-2 Chinese cities.
